Article Text

Download PDFPDF
Motor neuron disease
  1. Kevin Talbot
  1. Correspondence to Kevin Talbot, Reader in Clinical Neurology, University of Oxford, West Wing, John Radcliffe Hospital, Oxford, OX3 9DU, UK; kevin.talbot{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


The existence of a large number of neurological diseases in which the motor neuron is the principal site of pathology suggests that these cells and their neuronal networks have a specific set of vulnerabilities. Recent research, largely based on relatively rare genetic forms of motor neuron disease, indicates that these cells are vulnerable to defects in excitotoxicity, RNA transport and splicing, axonal protein transport, mitochondrial function, protein misfolding and oxidative stress. The most important motor neuron disease is a largely sporadic, late onset, degenerative condition, known simply as motor neuron disease (MND) or more widely as amyotrophic lateral sclerosis (ALS), which currently remains untreatable and uniformly fatal.

The core features of MND

In essence, MND is a progressive motor syndrome with clinical evidence of upper motor neuron dysfunction (spasticity, brisk reflexes, extensor plantar responses) and denervation (muscle wasting, weakness and fasciculation). It is typically asymmetrical in onset and progresses in a non-random pattern suggesting a pathological process with a focal onset and anatomically contiguous spread. Although predominantly a motor disorder, there is evidence of multisystem involvement (especially cognitive, but occasionally sensory or autonomic). The diagnosis is clinical, although imaging is usually necessary to exclude structural pathology mimicking MND. Neurophysiology should not be considered to be a diagnostic test but can provide support for the presence of denervation and exclude other conditions such as pure motor inflammatory demyelinating neuropathies.

  • The incidence of MND is approximately 2/100 000 population per year and there is no convincing evidence of geographical variation, although studies to date are limited to developed societies with predominantly European genetic heritage. Approximately 1/1000 death certificates list MND as the cause of death. There is no indication that MND is increasing in frequency.

  • The prevalence is approximately 7/100 000. General practitioners in the UK might encounter a patient with MND less than once every 10 years.

  • The …

View Full Text

Linked Articles

  • Editor’s choice
    Charles Warlow

Other content recommended for you